VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	7/7/2009 2:41:51 PM
	of 1972

Vical Incorporated announced that the company will report tomorrow the interim efficacy results from the company's Phase 2 trial evaluating the potential for its TransVax therapeutic DNA vaccine to prevent cytomegalovirus reactivation and disease in immunosuppressed stem cell transplant recipients. CMV and organ transplant expert Mark D. Pescovitz, M.D., Professor of Surgery and Microbiology & Immunology, and Vice Chair of Research in Surgery at the Indiana University School of Medicine, is scheduled to join Vical management on the call. :theflyonth

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next